Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing
Source: Bioprocess Online
![123412341 123412341](https://vertassets.blob.core.windows.net/image/73c75604/73c75604-bc51-4cc7-aba7-30d8f18477e6/375_250-123412341.png)
Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more